Galactosemia cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
 
Line 4: Line 4:


==Overview==
==Overview==
The cost-effectiveness of the therapy of [[galactosemia]] has primarily been studied with respect to the [[screening]] program for the [[disease]] and the benefits reaped from it.


==Cost-Effectiveness of Therapy==
==Cost-Effectiveness of Therapy==

Latest revision as of 22:38, 5 July 2022

Galactosemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Galactosemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Galactosemia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Galactosemia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Galactosemia cost-effectiveness of therapy

CDC on Galactosemia cost-effectiveness of therapy

Galactosemia cost-effectiveness of therapy in the news

Blogs on Galactosemia cost-effectiveness of therapy

Directions to Hospitals Treating Galactosemia

Risk calculators and risk factors for Galactosemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]

Overview

The cost-effectiveness of the therapy of galactosemia has primarily been studied with respect to the screening program for the disease and the benefits reaped from it.

Cost-Effectiveness of Therapy

The screening cost of galactosemia is less than the benefits i.e. QALYs achieved through screening, thereby making its implementation cost-effective[1]. Moreover, decreasing the false-positives [2], using healthcare information systems[3] and economical diagnostic techniques, establishing a centralized laboratory [4] and combining with other screening programs [5] will help in further reducing the financial burden. The efficiency of the neonatal screening policy is also inversely related to the prevailing interest rate in the economy[6].

References

  1. Hatam N, Askarian M, Shirvani S, Siavashi E (2017). "Neonatal Screening: Cost-utility Analysis for Galactosemia". Iran J Public Health. 46 (1): 112–119. PMC 5401919. PMID 28451536.
  2. Carroll AE, Downs SM (2006). "Comprehensive cost-utility analysis of newborn screening strategies". Pediatrics. 117 (5 Pt 2): S287–95. doi:10.1542/peds.2005-2633H. PMID 16735255.
  3. Hsieh SH, Hsieh SL, Chien YH, Weng YC, Hsu KP, Chen CH; et al. (2010). "Newborn screening healthcare information system based on service-oriented architecture". J Med Syst. 34 (4): 519–30. doi:10.1007/s10916-009-9265-x. PMID 20703906.
  4. Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Dunø M; et al. (2012). "Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening". Mol Genet Metab. 107 (3): 281–93. doi:10.1016/j.ymgme.2012.06.006. PMID 22795865.
  5. Padilla CD, Lam ST (2008). "Issues on universal screening for galactosemia". Ann Acad Med Singap. 37 (12 Suppl): 39–3. PMID 19904445.
  6. Camelo JS, Fernandes MI, Maciel LM, Scrideli CA, Santos JL, Camargo AS; et al. (2009). "Galactosaemia in a Brazilian population: high incidence and cost-benefit analysis". J Inherit Metab Dis. 32 Suppl 1: S141–9. doi:10.1007/s10545-009-1112-1. PMID 19418240.

Template:WH Template:WS